Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJESH PAHWA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1255438164
CMS profile
283548
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$100,416.61

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $88,405.00 33
Travel and Lodging $8,872.14 44
Food and Beverage $3,134.96 66
Education $4.51 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
MDD US Operations, LLC $35,265.59 58
Kyowa Kirin, Inc. $21,525.07 23
MITSUBISHI TANABE PHARMA AMERICA, INC. $10,714.15 11
ABBVIE INC. $10,366.57 10
Neurocrine Biosciences, Inc. $7,129.93 12
Merz Pharmaceuticals, LLC $4,847.36 3
ConvaTec Inc. $3,500.00 1
Cala Health, Inc. $3,023.74 3
Genentech, Inc. $3,000.00 2
Abbott Laboratories $885.97 17
Amneal Pharmaceuticals LLC $121.74 3
Medtronic, Inc. $36.49 1

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJESH PAHWA

NPI 1255438164 · CMS profile ID 283548

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255438164?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJESH PAHWA, NPI 1255438164, CMS profile ID 283548. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255438164?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RAJESH PAHWA, NPI 1255438164, CMS profile ID 283548. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255438164?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RAJESH PAHWA, NPI 1255438164, CMS profile ID 283548, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1255438164?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $100,416.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neurocrine Biosciences, Inc. $41.8504/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220005 CMS
Neurocrine Biosciences, Inc. $66.5004/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220009 CMS
Neurocrine Biosciences, Inc. $17.7104/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220013 CMS
Neurocrine Biosciences, Inc. $7.4004/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220017 CMS
Neurocrine Biosciences, Inc. $34.3404/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220021 CMS
Neurocrine Biosciences, Inc. $78.9504/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220025 CMS
Neurocrine Biosciences, Inc. $100.6104/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220029 CMS
Neurocrine Biosciences, Inc. $418.0604/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052220033 CMS
ABBVIE INC. $700.0004/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998060473 CMS
Kyowa Kirin, Inc. $2,625.0004/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018137 CMS
Kyowa Kirin, Inc. $321.0004/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018141 CMS
Kyowa Kirin, Inc. $660.9804/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018147 CMS
Kyowa Kirin, Inc. $117.9804/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018151 CMS
Kyowa Kirin, Inc. $16.9504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018157 CMS
Kyowa Kirin, Inc. $46.0004/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018161 CMS
Kyowa Kirin, Inc. $36.3904/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018167 CMS
Kyowa Kirin, Inc. $80.4604/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018171 CMS
Kyowa Kirin, Inc. $70.4304/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018175 CMS
Kyowa Kirin, Inc. $65.5004/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018181 CMS
Kyowa Kirin, Inc. $3,750.0004/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018187 CMS
Kyowa Kirin, Inc. $1,125.0004/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027018191 CMS
ABBVIE INC. $2,800.0004/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998060471 CMS
MDD US Operations, LLC $141.6704/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889433 CMS
MDD US Operations, LLC $45.0004/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889437 CMS
MDD US Operations, LLC $340.8804/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889443 CMS
MDD US Operations, LLC $246.4504/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889447 CMS
MDD US Operations, LLC $29.7704/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889451 CMS
MDD US Operations, LLC $78.1304/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889459 CMS
MDD US Operations, LLC $77.1304/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889461 CMS
MDD US Operations, LLC $90.6604/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889467 CMS
MDD US Operations, LLC $27.0604/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889471 CMS
MDD US Operations, LLC $30.6504/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889419 CMS
MDD US Operations, LLC $132.5604/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889425 CMS
MDD US Operations, LLC $176.0004/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889429 CMS
MDD US Operations, LLC $250.0003/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889409 CMS
MDD US Operations, LLC $250.0003/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889415 CMS
ConvaTec Inc. $3,500.0003/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057550583 CMS
Amneal Pharmaceuticals LLC $23.9703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053522579 CMS
Merz Pharmaceuticals, LLC $4,100.0003/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048308243 CMS
Merz Pharmaceuticals, LLC $11.3503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048308249 CMS
Merz Pharmaceuticals, LLC $736.0103/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048308255 CMS
Cala Health, Inc. $2,500.0002/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051478971 CMS
Cala Health, Inc. $500.0002/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051478977 CMS
MDD US Operations, LLC $2,070.0002/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052889405 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $219,723.97 248
PY2020 $152,247.71 90
PY2021 $57,879.12 57
PY2022 $136,412.80 113
PY2023 $100,416.61 144
PY2024 $96,233.70 131
PY2025 $126,282.37 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $432,921.42 77
PY2024 Principal investigator $653,693.34 86
PY2023 Principal investigator $637,314.13 79
PY2022 Principal investigator $373,254.93 82
PY2021 Principal investigator $554,272.31 123
PY2020 Recipient $3,000.00 1
PY2020 Principal investigator $658,611.60 111
PY2019 Recipient $5,280.00 3
PY2019 Principal investigator $824,488.70 211

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson s disease No dispute reported 06/30/2026 1202535089
Principal investigator 1 Roche TCRC, Inc. $134.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677928
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,354.77 12/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046750
Principal investigator 1 ABBVIE INC. $2,259.49 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202526714
Principal investigator 1 ABBVIE INC. $405.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDI
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202524758
Principal investigator 1 Abbott Laboratories $1,148.50 11/17/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE
NCT04071847--Abbott DBS Post-Market Study of Outcomes for Indications Over Time No dispute reported 06/30/2026 1248159566
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.45 11/14/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046744
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.00 11/14/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046746
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $130.00 11/14/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046748
Principal investigator 1 Abbott Laboratories $624.00 11/12/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04071847--Abbott DBS Post-Market Study of Outcomes for Indications Over Time No dispute reported 06/30/2026 1248159378
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $959.00 11/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242366003
Principal investigator 1 ABBVIE INC. $9,037.96 11/05/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202521557
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,200.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242365757
Principal investigator 1 ABBVIE INC. $461.51 11/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202520217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.45 10/23/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046742
Principal investigator 1 ABBVIE INC. $201.00 10/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDI
a glogal real world evidence study on the long term effect of abbv-951 No dispute reported 06/30/2026 1202517711
Principal investigator 1 ABBVIE INC. $201.00 10/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202518097
Principal investigator 1 Roche TCRC, Inc. $5,378.40 10/14/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677924
Principal investigator 1 Saluda Medical Americas, Inc. $5,192.10 10/10/2025 Non-covered Recipient Entity
University of Kansas Medical Center
ECAP-PD No dispute reported 06/30/2026 1236865267
Principal investigator 1 ABBVIE INC. $6,778.47 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202514833
Principal investigator 1 Roche TCRC, Inc. $67.00 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677926
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,116.30 09/23/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046740
Principal investigator 1 Roche TCRC, Inc. $1,792.80 09/11/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677916
Principal investigator 1 ABBVIE INC. $11,701.27 09/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202508586
Principal investigator 1 Roche TCRC, Inc. $134.00 08/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677914
Principal investigator 1 Abbott Laboratories $2,090.00 08/21/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04071847--Abbott DBS Post-Market Study of Outcomes for Indications Over Time No dispute reported 06/30/2026 1248155796
Principal investigator 1 Roche TCRC, Inc. $134.00 08/14/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677918
Principal investigator 1 Roche TCRC, Inc. $5,559.30 08/14/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677920
Principal investigator 1 Roche TCRC, Inc. $67.00 08/14/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677922
Principal investigator 1 Abbott Laboratories $687.00 08/13/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE
NCT04071847--Abbott DBS Post-Market Study of Outcomes for Indications Over Time No dispute reported 06/30/2026 1248155434
Principal investigator 1 Saluda Medical Americas, Inc. $10,806.01 08/08/2025 Non-covered Recipient Entity
University of Kansas Medical Center
ECAP-PD No dispute reported 06/30/2026 1236865263
Principal investigator 1 Saluda Medical Americas, Inc. $20,000.00 08/08/2025 Non-covered Recipient Entity
University of Kansas Medical Center
ECAP-PD No dispute reported 06/30/2026 1236865265
Principal investigator 1 ABBVIE INC. $5,406.75 08/06/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202503579
Principal investigator 1 ABBVIE INC. $6,380.01 08/05/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202502202
Principal investigator 1 UCB SA $8,370.00 07/31/2025 Non-covered Recipient Entity
KU INFECTIOUS DISEASE
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658752
Principal investigator 1 ABBVIE INC. $67.00 07/30/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202500448
Principal investigator 1 ABBVIE INC. $18,250.00 07/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497094
Principal investigator 1 Sage Therapeutics, LLC $9,982.65 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment No dispute reported 06/30/2026 1206580435
Principal investigator 1 Roche TCRC, Inc. $7,344.00 06/13/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677908
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $959.00 06/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242348768
Principal investigator 1 ABBVIE INC. $2,959.25 06/03/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202488151
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $889.00 06/01/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046738
Principal investigator 1 ABBVIE INC. $8,104.82 05/29/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Participants With Parkinson Disease (PD) No dispute reported 06/30/2026 1202486787
Principal investigator 1 Genentech, Inc. $1,406.00 05/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211678021
Principal investigator 1 Roche TCRC, Inc. $134.00 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677910
Principal investigator 1 Roche TCRC, Inc. $67.00 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677912
Principal investigator 1 Genentech, Inc. $38,117.00 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211678031
Principal investigator 1 ABBVIE INC. $9,094.25 05/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202485167
Principal investigator 1 ABBVIE INC. $460.34 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202484557
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,100.00 05/08/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046732
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,650.00 05/08/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046734
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 05/08/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046736
Principal investigator 1 ABBVIE INC. $2,959.25 05/06/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202482153
Principal investigator 1 ABBVIE INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202480847
Principal investigator 1 Roche TCRC, Inc. $1,500.00 04/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677904
Principal investigator 1 Roche TCRC, Inc. $134.00 04/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677906
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,004.00 04/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242339420
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $868.00 04/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242339454
Principal investigator 1 Roche TCRC, Inc. $335.00 03/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677898
Principal investigator 1 ABBVIE INC. $31,709.86 03/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202465790
Principal investigator 1 ABBVIE INC. $923.02 03/06/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202457789
Principal investigator 1 Sage Therapeutics, LLC $591.16 03/06/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580431
Principal investigator 1 ABBVIE INC. $1,745.00 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202453415
Principal investigator 1 Roche TCRC, Inc. $134.00 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677902
Principal investigator 1 Abbott Laboratories $460.00 02/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE
NCT04071847--Abbott DBS Post-Market Study of Outcomes for Indications Over Time No dispute reported 06/30/2026 1248146320
Principal investigator 1 Genentech, Inc. $75,658.00 02/07/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211678023
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $959.00 02/07/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242330293
Principal investigator 1 UCB SA $13,567.79 02/03/2025 Non-covered Recipient Entity
KU INFECTIOUS DISEASE
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246658336
Principal investigator 1 Sage Therapeutics, LLC $14,202.50 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580228
Principal investigator 1 ABBVIE INC. $3,240.46 01/16/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202439825
Principal investigator 1 Roche TCRC, Inc. $15,417.00 01/16/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677896
Principal investigator 1 Roche TCRC, Inc. $134.00 01/16/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211677900
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,497.00 01/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242328530
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,522.00 01/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242328532
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $959.00 01/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242328556
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,255.00 01/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
ITI-214-202 No dispute reported 06/30/2026 1242328558
Principal investigator 1 UCB SA $4,908.53 01/08/2025 Non-covered Recipient Entity
KU INFECTIOUS DISEASE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246657330